Amylyx Pharmaceuticals Announces Pricing of an Upsized $500 Million Underwritten Public Offering of Common Stock

Amylyx Pharmaceuticals Announces Pricing of an Upsized $500 Million Underwritten Public Offering of Common Stock

Client News

Related Solutions

Leveraging our sophisticated technical, market and legal experience to help clients effectively and efficiently manage complex transactions and get the deal done.
Advising life sciences innovators, investors and industry leaders on complex transactions, legal issues and business challenges.
WilmerHale advised the underwriters in the public offering of 16,203,500 shares of common stock of Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX), at a public offering price of $35.50 per share, including the full exercise of the underwriters’ option to purchase an additional 2,113,500 shares of common stock. Amylyx is a clinical-stage  pharmaceutical company with a mission to develop and advance novel therapies for communities with high unmet medical needs.  Total gross proceeds from the offering, including the exercise of the underwriters’ option to purchase additional shares, were approximately $575 million, excluding underwriting discounts, commissions and other offering-related expenses. The offering priced on August 19, 2026, and closed on August 21, 2026.

The WilmerHale team was led by Lisa Firenze and included Hilary Baker-Jennings, Amy O’Connell and Sophie Bonadeo, with assistance from Barish Ozdamar on intellectual property matters, George O’Brien on regulatory matters, and Meghan Walsh on tax matters.
 

Notice

We appreciate your interest in WilmerHale. While we are pleased to have you contact us, please keep in mind that merely contacting WilmerHale does not create an attorney-client relationship. Such a relationship will not arise until the Firm agrees in writing to represent you in connection with a particular matter. Importantly, unless and until this has occurred, you should not provide us with any confidential information, and we have no duty to keep confidential any information that we may receive from you. Thank you for your understanding.

I Accept Cancel